Caitlin Raymond: When to Use Albumin vs. Plasma, and Why the Timing Matters
Caitlin Raymond, a board-certified Clinical Pathologist and current Transfusion Medicine Fellow at the National Institutes of Health, shared on LinkedIn:
“The Overlooked Half of the Exchange
When we talk about plasma exchange, most discussions stop at what we’re removing — antibodies, paraproteins, cytokines. But that’s only half the story.
Replacement fluid is the other half — and it quietly dictates safety, hemostasis, and recovery.
The right choice isn’t just technical; it’s clinical judgment in action.
In my latest blog post, I break down:
- When to use albumin vs. plasma, and why the timing matters
- How combination strategies (like 50:50 albumin–FFP) can balance practicality and bleeding risk
- Common myths and misconceptions — including why “albumin is always safer” isn’t true
Real-world scenarios: TTP, transplant desensitization, AMR, and more
Read the full post here.
Choosing the replacement fluid isn’t just following a protocol — it’s the art within the algorithm.
ecause in apheresis, the machines may be automated, but judgment isn’t.”

Stay updated with Hemostasis Today.
-
Jul 20, 2026, 13:18Ekaterina Balaian: Submission Open for Special Issue on Hematologic Metabolism
-
Jul 20, 2026, 12:54Victor Emmanuel: Preventing Severe Maternal Complications Associated With Anemia
-
Jul 20, 2026, 12:33Ney Carter Borges: The Evolving Role of Aspirin in Coronary Artery Disease
-
Jul 20, 2026, 12:15Zain Khalpey: Why the Cause of Reduced Perfusion Matters
-
Jul 20, 2026, 11:53ISTH 2026 Showcases Landmark Research and Launches Women’s Health Hub
-
Jul 20, 2026, 10:40Omid Seidizadeh: Advancing Genomic Insights into Bleeding Disorders at ISTH 2026
-
Jul 20, 2026, 10:30Marc Blondon: What Are the Current Practices For VTE Prevention in Pregnancy Worldwide?
-
Jul 20, 2026, 10:11Zeyad Bady: Advancing Thrombosis Research on the International Stage at ISTH 2026
-
Jul 20, 2026, 09:41Emily Bury: From Emerging Evidence to Better Patient Care at ISTH 2026